<DOC>
	<DOCNO>NCT01705223</DOCNO>
	<brief_summary>This trial study safety immunogenicity HIV clade B'/C DNA vaccine follow recombinant vaccinia virus rTV boost HIV-uninfected healthy volunteer low high risk HIV infection . In addition , effect different interval prime-boost study .</brief_summary>
	<brief_title>Safety Immunogenicity Study AIDS Vaccine ( Combined Use DNA Vaccine Recombinant Vaccinia Virus Tiantan )</brief_title>
	<detailed_description />
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing follow plan duration study , receive intravenous blood collection sample storage 16~20 month first vaccination ; Understand agree content informed consent ; Volunteers low risk HIV infection , highrisk men sex men ( MSM） , oral sex anal sex another man past 6 month ; Willing test HIV syphilis ; Before 2 week first vaccination 12 month last vaccination , willing use effective method contraception sexual partner . Female subject willing undergo urine pregnancy test vaccination followup visit . Have close contact people pregnant lactate one month vaccination rTV vaccine ; Have list disease medical history : Have innate acquire immune deficiency disease close contact patient suffer abovementioned disease within 1 month rTV vaccination ; Need treatment affect immunization , e.g . use corticosteroid 2 week use immunosuppressive , e.g . alkylating , antimetabolite radiotherapy , etc . ; close contact patient suffer abovementioned disease within 1 month rTV vaccination ; Suffering immunosuppressive disease cancer , organ stem cell transplant , nonagammaglobulinemia , etc . ; close contact patient suffer abovementioned disease within 1 month rTV vaccination ; Past current suffering eczema atopic dermatitis ; currently suffer disease cause skin damage : burn , scald , chicken pox , impetigo , shingle , psoriasis , etc . ; close contact patient suffer abovementioned disease within 1 month rTV vaccination ; Past current high blood pressure , heart disease , diabetes , thyroid disease , asthma , angioedema , asplenia syndrome , mental illness , epilepsy , severe anemia , leukopenia thrombocytopenia , etc . ; History syncope vaccination allergy ; Currently suffer acute infectious disease febrile diseases； The following circumstance : Live attenuate vaccine receive within 2 month vaccine within 2 week prior enrollment ; Immunoglobin blood product receive within 4 month prior enrollment ; Participation another trial medicinal product , complete less 30 day prior enrollment ; Drug abuse , alcoholism , heavy smokers； The following laboratory test abnormality , except result assess researcher clinical significance： HIV diagnostic assay positive suspicious , HIV RNA diagnostic assay positive ; AntiDNA antibody antinuclear antibody positive ; Other laboratory test abnormality ; Not comply study protocol obtain informed consent medical , spiritual , social , occupational , and/or reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>prophylactic</keyword>
	<keyword>vaccine</keyword>
</DOC>